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Lack of association of the 463G/A myeloperoxidase promoter
polymorphism with Behc¸et’s disease in Italian patients
F. Atzeni, L. Boiardi1, B. Casali2, E. Farnetti2, P. Sarzi-Puttini, N. Pipitone1, I. Olivieri3, F. Cantini4,
F. Salvi5, R. La Corte6, G. Triolo7, D. Filippini8, G. Paolazzi9 and C. Salvarani1
Objective. To investigate potential associations between the 463G/A myeloperoxidase (MPO) promoter polymorphism and susceptibility
to, and clinical expression of, Behc¸et’s disease (BD).
Methods. One hundred and seventy-five Italian patients who satisfied the International Study Group criteria for BD and 235 healthy age- and
sex-matched blood donors were genotyped for the 463G/A promoter polymorphism of the MPO gene by molecular methods. The patients
were subgrouped according to the presence or absence of clinical manifestations.
Results. The distribution of allele and genotype frequencies of the MPO 463A/G polymorphism did not differ significantly between the
BD patients and the healthy controls. Carriers of the 463A allele (A/A or A/G) [odds ratio (OR) 0.7, 95% confidence interval (CI) 0.5–1.1]
and homozygosity for A allele (OR 0.3, 95% CI 0.1–1.3) were less frequent among BD patients than among the controls, but the difference
was not statistically significant. No significant associations were found when BD patients with and those without clinical manifestations were
compared.
Conclusion. Our data suggest that the 463G/A promoter polymorphism of the MPO gene is not associated with susceptibility to,
and clinical expression of, BD in Italian patients.
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Behc¸et’s disease (BD) is a multi-systemic inflammatory disorder,
which preferentially affects oral and genital mucous membranes,
skin and eyes [1–3]. Arthritis, gastrointestinal, vascular and
central nervous system (CNS) involvement may also be present.
Vasculitis is the pathological lesion underlying most clinical
manifestations of BD. BD has a distinctive geographical distribu-
tion, with the highest prevalence in countries along the ancient
‘Silk Route’, including Italy, Turkey, Iran, China and Japan [1–3].
The aetiology of BD is largely unknown, but genetic and
environmental factors are probably involved [1–3].
Myeloperoxidase (MPO) is a haeme-containing peroxidase
expressed and stored in neutrophils and monocytes, which,
during cellular activation and degranulation, is released into
phagocytic vacuoles as well as into the extracellular space [4, 5].
MPO catalyses a reaction between hydrogen peroxide and
chloride to generate hypochlorous acid (HOCl), a potent oxidant
and chlorinating agent that can cause vascular damage when
released by activated cells at inflammatory sites [6, 7].
Investigations have shown that various functions of neutrophils
in peripheral blood, such as chemotaxis, phagocytosis and
generation of reactive oxygen species (ROS) are enhanced in BD
[8–12]. High levels of MPO have been found in both plasma and
supernatants of neutrophil cultures from patients with active BD
[13–15]. Therefore, activated neutrophils and MPO may play a
central role in the pathophysiology of BD.
The promoter region of the MPO gene has a single G-to-A base
substitution at position 463, which has been reported to be
functionally important since it influences MPO expression [16–18].
The GG genotype is associated with higher levels of MPO mRNA
expression and higher levels of MPO protein than GA/AA
genotypes [16–18]. Several diseases have been reported to
be associated with the 463G/A MPO promoter polymorphism
[19–24]. Recently, MPO-antineutrophil cytoplasmic autoanti-
bodies (ANCA)-associated vasculitis was found to be associated
with GG genotype in females but not in males [22]. Moreover,
GA/AA genotype was associated with an increased incidence
of relapse and an earlier age at diagnosis. These results suggest
that a genetically determined regulation of MPO expression
may be implicated in the pathogenesis and clinical expression of
vasculitis.
The aim of our study was to assess the role of this MPO
promoter polymorphism in the susceptibility to and clinical
expression of BD in a cohort of Italian patients.
Materials and methods
Study population
Case patients were 175 consecutive patients with BD who were
followed in nine different Italian referral centers [25] over a
7-yr period (1999–2005). All patients fulfilled the criteria
developed by the International Study Group for BD (ISG) [26].
The control group consisted of 235 gender- and age-matched
healthy subjects who were unrelated volunteer blood donors. The
median age of the controls was 34 yrs (range 19–44), 50% of
whom were males. All study subjects were Caucasians who had
been residing in Italy for at least one generation. No ethnic
differences were present between patients and controls. Written
informed consent was obtained from patients and controls before
inclusion in the study. The study was approved by the Ethics
Committees of the participating centres.
HLA class I typing
Serological HLA class I typing was performed by a standard
microlymphocytotoxicity technique, using peripheral blood
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lymphocytes [27]. Out of the 175 Italian patients with BD,
151 were typed for HLA-B51 allele.
DNA extraction and genotyping
DNA was extracted from peripheral blood leucocytes using
phenol/chloroform method, according to standard procedures
[28]. Polymorphisms were detected by using RFLP-PCR analysis
as described by London et al. [21]. A 350-bp DNA fragment
was amplified using forward primer MPOF (50-CGG TAT AGG
CAC ACA ATG GTG AG-30) and reverse primer MPOR (50-
GCA ATG GTT CAA GCGATT CTT C-30).
PCR amplification was performed in 25l reaction containing
100M of each dNTP, 20 pmol each primer, 1 unit Taq
polymerase. Amplification profile was as follows:
 initial denaturation 958C for 2min;
 35 cycles of: 948C for 30 s, 628C for 30 s, 728C for 30 s;
 final extension at 728C for 3min.
PCR products were digested with the restriction enzyme AciI.
This enzyme can reveal the presence of an A or G nucleotide at the
463 position. Electrophoresis analysis of digested PCR products
was performed in 2% agarose gel stained with ethidium bromide
(0.5g/ml) to show patterns for the three genotypes: 169, 120
and 61 bp fragments for the homozygous wild-type (463GG);
289, 169, 120 and 61 bp fragments for the heterozygous type
(463AG); and 289 and 61 bp fragments for the homozygous
mutant type.
Statistical analysis
Statistical analysis was performed using SPSS statistical package
(SPSS Inc., Chicago, IL, USA). The frequencies of the alleles and
genotypes among the case patients and control group were
compared by chi-squared test. Odds ratios (ORs) were calculated
together with their 95% confidence intervals (95% CIs).
We performed a power calculation for an unmatched case-control
study and estimated relative risk using Power and Sample Size
Calculation version 2.1.31 software.
Results
The demographic and clinical characteristics of the 175 Italian
patients with BD are reported in Table 1.
The allele and genotype frequencies of the 463GA MPO
promoter polymorphism in BD patients and in the control group
are shown in Table 2. The distribution of the MPO-G/A genotype
did not differ significantly between BD patients and the controls,
although the GG genotype was more frequent in BD patients as
compared with the controls (61.1 vs 53.6%, respectively).
Allele G frequency was similar in BD patients and controls
(79.7 vs 74.5%, respectively). Carriers of the A allele (AA or AG)
were less frequent among the BD patients than among the controls
(OR 0.7, 95% CI 0.5–1.1). Homozygosity for the A allele was also
less frequent in BD patients than in controls (OR 0.3, 95% CI
0.1–1.3). However, these differences were not statistically
significant.
Given the sample sizes (175 patients with BD and 235 controls)
and the allele frequencies of the polymorphism examined, we can
conclude with 80% certainty that there is a genetic relative risk of
1.53 for BD in carriers of the 463GA MPO promoter
polymorphism.
Since a study [22] has shown that the influence of the MPO-G/
A polymorphism could be gender-specific, we compared the
influence of MPO genotype in BD females and BD males. No
influence of gender was observed (data not shown). We confirmed
that in either BD females and BD males there was no association
with the MPO-G/A polymorphism.
The associations between the 463GA MPO polymorphism
and the clinical manifestations of BD defined in Table 1 were
evaluated in the 175 BD patients, comparing patients with
and without manifestations. No significant associations were
found (data not shown). Carriers of the A allele (AA or AG) were
less frequent in BD patients with anterior uveitis than in those
without (29.6 vs 43.0%), but the difference was not statistically
significant.
Discussion
BD is a polygenic disease in which multiple genetic factors, in
combination with environmental risk factors such as infectious
agents, are probably of importance in determining disease
susceptibility and clinical expression [1–3]. Although the strongest
genetic association identified in BD has been with HLA-B51 and
MICA-A6 alleles [1–3, 29], recent studies have found that R/G 241
polymorphism of ICAM-1 gene [30], Glu/Asp 298 polymorphism
of eNOS gene [31] and 634C/G polymorphism of VEGF gene
[32] are associated with BD susceptibility in the Italian
population.
Vasculitis is the pathological lesion underlying most of the
clinical findings of BD. In one immunopathological study,
Kobayashi et al. [33] showed that the predominant lesion in
vasculo-Behc¸et’s is a neutrophilic vasculitis involving the vasa
vasorum. Further, these authors showed that neutrophils and
endothelial cells of the vasa vasorum are activated. Several studies
have found that patients with BD have increased plasma MPO
activity, reflecting neutrophil activation [13–15]. Yazici et al. [13]
TABLE 1. Demographic and clinical features of 175 Italian patients with Behc¸et’s
disease
Number Percentage
Female/Male 80/95 45.7/54.3
Mean age at disease onset S.D. (yrs) 3012
Mean disease duration (yrs) 118
Oral ulcers 175 100
Cutaneous lesions 146 83.4
Papulopustular lesions 94 53.7
Erythema nodosum 75 42.9
Genital ulcers 109 62.3
Epididymitis 12 6.9
Eye lesions 98 56.0
Anterior uveitis 54 30.9
Posterior uveitis and retinal vasculitis 77 44.0
Arthritis 75 42.9
Central nervous system involvement 30 17.1
Venous thrombosisa 48 27.4
Deep venous thrombosis 33 18.9
Positive pathergy testb 41/102 40.2
HLA-B51c 95/151 62.9
aSubcutaneous thrombophlebitisþ deep vein thrombosis.
bPathergy test was performed on 102 patients.
cHLA-B51 was performed on 151 patients.
TABLE 2. Frequencies of alleles, genotypes and carriage rates of MPO
polymorphism in patients with Behc¸et’s disease and controls
Behc¸et’s disease
(n¼ 175)
Controls
(n¼235) P OR (95% CI)
Allele
A 71/350 (20.3) 120/470 (25.5) 0.08 0.7 (0.5–1.0)
G 279/350 (79.7) 350/470 (74.5)
Genotypes
A/A 3/175 (1.7) 11/235 (4.7)
A/G 65/175 (37.1) 98/235 (41.7) 0.128
G/G 107/175 (61.1) 126/235 (53.6)
Carriage rate
A/AþA/G 68/175 (38.9) 109/235 (46.4) 0.13 0.7 (0.5–1.1)
G/G 107/175 (61.1) 126/235 (53.6)
A/GþG/G 172/175 (98.3) 224/235 (95.3) 0.17 0.3 (0.1–1.3)
A/A 3/175 (1.7) 11/235 (4.7)
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found strong positive correlations between MPO, erythrocyte
sedimentation rate and C-reactive protein levels in patients with
BD, suggesting the presence of a relationship between the extent
of inflammation and neutrophil activation. Several investigations
have shown in BD patients an increased ROS production
by neutrophils [9–12] and a decreased superoxide scavenging
activity in both neutrophils and plasma [34–38]. Therefore,
a disrupted oxidant/antioxidant equilibrium may play an
important role in tissue injury and in the inflammatory
reaction in BD. Recently, Yazici et al. [13] showed that the
neutrophil–MPO–HOCL system oxidizes plasma proteins in
patients with BD. Further, these authors showed that patients
with active disease had significantly higher plasma levels of
MPO and advanced oxidation protein products (AOPP), which is
one of the products of MPO-mediated protein oxidation,
compared with patients with inactive disease and healthy
controls [13]. MPO may determine vascular damage by several
mechanisms. MPO has been shown to activate metalloproteinase
and catalytically consume endothelium-derived NO by reducing
its bioavailability and impairing its vasodilatory and anti-
inflammatory functions [6]. Endothelial dysfunction evaluated
by endothelium-dependent vasodilation occurs in BD patients
[39]. Furthermore, NO production was found to be decreased in
patients with active disease compared with the inactive period
and the control group [39]. Taken together, these observations
indicate that neutrophil activation and MPO may have an
important role in the pathogenesis of vascular lesions in BD.
A functional promoter polymorphism has been identified in
the promoter region of the MPO gene, consisting of a G to A
substitution. The 463G/A polymorphism is situated within
an Alu-encoded hormone response element and creates a SP1
site in the G allele promoter, and an oestrogen receptor- binding
site in the A promoter. The GG genotype is associated with a 2- to
3-fold higher expression of MPO messenger RNA and protein
expression than GA/AA genotypes [16–18].
The high-expression GG genotype has been associated with
an increased risk of Alzheimer’s disease [19], multiple sclerosis
[40], while the low-expression genotypes (AG and AA) have a
protective role in coronary artery disease [23, 41, 42].
A genetically determined regulation of MPO expression may
be implicated in the pathogenesis and clinical expression of
vasculitis. The studies that have evaluated the association between
MPO promoter polymorphism and vasculitis have reported
discordant results. Reynolds et al. [22] observed that MPO-
ANCA-associated vasculitis was associated with GG genotype in
females but not in males. Moreover, GA/AA genotype was
associated with an increased incidence of relapse and an earlier
age at diagnosis. We recently found that subjects homozygous for
the allele G have an increased risk of developing GCA [43]. The
results of these two studies suggest that a genetically determined
up-regulation of MPO expression may predispose to the develop-
ment of vasculitis. However, in contrast to the findings of
Reynolds et al. [22], no associations were observed in the study of
Fiebeler et al. [44] between the MPO promoter polymorphism and
MPO-ANCA-associated vasculitis.
One of the most important causes of failure to replicate
findings in genetic association studies of vasculitis is
the inadequacy of sample sizes. The number of patients with
MPO-ANCA-associated vasculitis studied by Reynolds et al. [22]
and by Fiebeler et al. [44] were 50 and 48 patients, respectively.
In this study, we evaluated the 463G/A polymorphism in an
ethnically homogeneous and large group of Italian patients with
BD. Although carriers of, and homyoygosity for, the A allele
were less frequent among the BD patients than among the
controls, suggesting that a genetically determined reduced
activity of MPO might be protective against the development of
BD, the differences were not statistically significant. However,
multicentre collaborations to recruit an adequate number of
patients are required.
A second aim of this study was to determine whether this MPO
polymorphism might be associated with the clinical expression of
BD in our cohort of Italian patients.
However, when patients with and without manifestations were
compared, no associations were found, although our study is
probably not sufficiently powered to detect significant associa-
tions between this MPO polymorphism and clinical
manifestations.
In conclusion, we did not find any association between the
463G/A MPO promoter polymorphism and susceptibility to,
and clinical expression of, BD. These results do not support the
hypothesis that a genetically determined regulation of MPO
expression may predispose to the development and clinical
expression of this vasculitis in Italian patients. Further, larger
studies are required to confirm our findings in other populations.
The authors have declared no conflicts of interest.
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